{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:38:42Z","timestamp":1767861522343,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1093\/jjco\/hyv045","type":"journal-article","created":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:50:49Z","timestamp":1430182249000},"page":"576-583","source":"Crossref","is-referenced-by-count":39,"title":["Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients"],"prefix":"10.1093","volume":"45","author":[{"given":"Hideyuki","family":"Akaza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Houzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Pitman Lowenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,4,27]]},"reference":[{"key":"key\n\t\t\t\t20170502104620_HYV045C1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170502104620_HYV045C2","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jjco\/hyp146","article-title":"A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety","volume":"40","author":"Uemura","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C4","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jjco\/hyq146","article-title":"Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma","volume":"40","author":"Tomita","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key\n\t\t\t\t20170502104620_HYV045C6","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.320","article-title":"Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU)","volume":"29","author":"Michaelson","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C7","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Dienstmann","year":"2011","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t20170502104620_HYV045C8","article-title":"Neutropenia and thrombocytopenia during treatment as biomarkers of sunitinib efficacy in patients with metastatic renal cell carcinoma","author":"Donskov","year":"2011"},{"key":"key\n\t\t\t\t20170502104620_HYV045C9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cncr.25422","article-title":"Hypothyroidism in patients with renal cell carcinoma: blessing or curse?","volume":"117","author":"Schmidinger","year":"2011","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170502104620_HYV045C10","author":"World Health Organization"},{"key":"key\n\t\t\t\t20170502104620_HYV045C11","author":"World Health Organization"},{"key":"key\n\t\t\t\t20170502104620_HYV045C12","author":"Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan"},{"key":"key\n\t\t\t\t20170502104620_HYV045C13","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/cncr.26440","article-title":"Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma","volume":"118","author":"Barrios","year":"2012","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170502104620_HYV045C14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jjco\/hyq073","article-title":"The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction","volume":"40","author":"Yoo","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C15","article-title":"An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma","author":"Lee","year":"2009"},{"key":"key\n\t\t\t\t20170502104620_HYV045C16","article-title":"Clinical outcome of Asian vs. non-Asian patients with metastatic renal cell carcinoma with continuous once-daily dosing of sunitinib as first-line therapy","author":"Barrios","year":"2010"},{"key":"key\n\t\t\t\t20170502104620_HYV045C17","first-page":"375","article-title":"Clinical study of sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience","volume":"48","author":"Li","year":"2010","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"key\n\t\t\t\t20170502104620_HYV045C18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C20","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C22","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e15098","article-title":"Efficacy and safety of sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC) and lung metastases (mets) only at baseline","author":"Shinohara","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C23","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","article-title":"A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma","volume":"50","author":"Najjar","year":"2014","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20170502104620_HYV045C24","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.urolonc.2013.10.004","article-title":"Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature","volume":"32","author":"Bjarnason","year":"2014","journal-title":"Urol Oncol"},{"key":"key\n\t\t\t\t20170502104620_HYV045C25","article-title":"Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma: results from a prospective registry in Singapore","author":"Tan","year":"2014","journal-title":"Clin Genitourin Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/45\/6\/576\/14097080\/hyv045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T11:49:19Z","timestamp":1598960959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article-lookup\/doi\/10.1093\/jjco\/hyv045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,27]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,4,27]]},"published-print":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyv045","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4,27]]}}}